Omeros Corporation (OMER) EPS Estimated At $-0.16

March 10, 2018 - By Vivian Currie

 Omeros Corporation (OMER) EPS Estimated At $ 0.16
Investors sentiment increased to 2.86 in 2017 Q3. Its up 1.59, from 1.27 in 2017Q2. It increased, as 10 investors sold Omeros Corporation shares while 11 reduced holdings. 22 funds opened positions while 38 raised stakes. 22.04 million shares or 15.32% more from 19.11 million shares in 2017Q2 were reported.
Susquehanna Int Limited Liability Partnership holds 0.01% or 705,812 shares in its portfolio. Fincl Bank Of Ny Mellon has 242,039 shares for 0% of their portfolio. 3,272 were accumulated by Royal Bancshares Of Canada. Tocqueville Asset Lp reported 0.12% in Omeros Corporation (NASDAQ:OMER). Ameritas Investment Prtn Inc reported 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Department Mb Finance State Bank N A reported 0.01% stake. The New York-based Ingalls Snyder Ltd Llc has invested 5.81% in Omeros Corporation (NASDAQ:OMER). Art Advsr Limited Liability Corp has 0.09% invested in Omeros Corporation (NASDAQ:OMER) for 84,135 shares. Great West Life Assurance Can reported 3,347 shares. Deutsche Commercial Bank Ag holds 0% or 47,964 shares in its portfolio. American Financial Grp Inc has invested 1.6% of its portfolio in Omeros Corporation (NASDAQ:OMER). 202,025 were accumulated by Eam Ltd Liability. California State Teachers Retirement has invested 0% in Omeros Corporation (NASDAQ:OMER). American International has invested 0% in Omeros Corporation (NASDAQ:OMER). 12,900 were accumulated by Amp Capital.

Since January 3, 2018, it had 0 insider buys, and 2 insider sales for $1.36 million activity. 1,020 shares valued at $22,899 were sold by JACOBSEN MICHAEL A on Wednesday, January 3.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.16 EPS on March, 15.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. After having $-0.07 EPS previously, Omeros Corporation’s analysts see 128.57 % EPS growth. The stock increased 6.89% or $0.73 during the last trading session, reaching $11.32. About 802,096 shares traded. Omeros Corporation (NASDAQ:OMER) has risen 42.59% since March 10, 2017 and is uptrending. It has outperformed by 25.89% the S&P500.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 9 analysts covering Omeros (NASDAQ:OMER), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Omeros has $75 highest and $1500 lowest target. $36.38’s average target is 221.38% above currents $11.32 stock price. Omeros had 28 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Wednesday, August 9. The stock has “Strong Buy” rating by WBB Securities on Tuesday, August 18. The stock of Omeros Corporation (NASDAQ:OMER) has “Hold” rating given on Friday, March 2 by Needham. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 23. The firm has “Buy” rating by Needham given on Wednesday, November 11. The company was maintained on Tuesday, June 13 by Maxim Group. As per Wednesday, August 2, the company rating was maintained by Maxim Group. Cantor Fitzgerald maintained the stock with “Hold” rating in Thursday, August 24 report. Needham maintained the shares of OMER in report on Thursday, November 10 with “Buy” rating. The rating was downgraded by Cowen & Co to “Market Perform” on Thursday, November 2.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $546.60 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More important recent Omeros Corporation (NASDAQ:OMER) news were published by: which released: “Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial …” on February 26, 2018, also published article titled: “Needham downgrades Omeros on soft Q4 Omidria sales”, published: “Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results” on March 01, 2018. More interesting news about Omeros Corporation (NASDAQ:OMER) was released by: and their article: “Is Omeros Corporation a Buy on the Dip?” with publication date: March 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.